Roberts CM, Lopez-Campos JL, Hartl S, Pozo-Rodriguez P. European hospi- tal adherence to GOLD recommendations for chronic obstructive pulmonary disease (COPD) exacerbation admissions. Thorax. 2013;68:1169-71.Roberts CM, Lopez-Campos JL, Pozo-Rodriguez F, Hartl S, European CAt. European ...
The 2023 GOLD Report, is the 5th major revision of GOLD, and Y P incorporates an update of information that has been reviewed by the science committee from 2021 to 2022 and a O C reassessment and revision of recommendations for the diagnosis, assessment and treatment of COPD. T O N O ...
Importantly, given that recommendations for pharmacotherapy for COPD are based on GOLD ABE groups, the impact of a lower ECOPD threshold on individual patient treatment, potential overtreatment, and related financial implications should be evaluated in future studies. In this study, 52.0% of patients...
TheGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) Reportprovides recommendations for COPD management. ItsABCD algorithmfor prescribinginhalertherapy — driven by patient symptoms and exacerbation history — is well known and widely used. If sym...
exacerbation prevention in the management of COPD. However, there were some important limitations to this scheme. The ABCD assessment tool performed no better than spirometric grades for mortality prediction or other important health outcomes. To address these and other concerns ...
REAL WORLD COMPLIANCE OF GOLD GUIDELINE AND INFLUENCE THE RISK OF COPD EXACERBATIONdoi:10.1111/resp.13207_251NoneJohn Wiley & Sons, LtdRespirology
COPD. Scientific information and recommendations for COPD programs. (November 2006) • Executive Summary, Global Strategy for the Diagnosis, Management, and Prevention of COPD. (December 2006) • Pocket Guide to COPD Diagnosis, Management, and Prevention. ...
1.GOLD2014.2.GroenewegenKH,etal.Mortalityandmortality-relatedfactorsafterhospitalizationforacuteexacerbationofCOPD.Chest,2003,124(2):459-467.长期使用全身激素是COPD患者死亡风险增加的独立危险因素2REDUCE研究:短期vs.传统激素治疗多中心,双盲,随机AECOPD患者(N=314)Day1甲强龙40mgivDay2~5泼尼松40mg/dDay1甲强...
1.2015GOLD的主要更新内容2.ICS在慢阻肺治疗中的地位3.支气管舒张剂是慢阻肺治疗的基石 2 GOLD简介(2006~2007)是一个策略工具-不仅仅是指南，每5年修订一次GOLD执行委员会颁布的2006版是一次较大修订GOLD2007-2010每年有小的更新GOLD2011进行了较大的修订 对慢阻肺评估方式和管理的模式有了较大的更新并涵盖了...
infections, including SARS-CoV-2. Future versions of GOLD will likely have evidence-based recommendations that include the long-term effects of air pollution, climate change, and COVID-19 on COPD, etiological subtypes of COPD, and advice for COPD prevention and management in low-income countries...